Dongin (Donoven) Kim, Ph.D.

---

Publications & Presentations

31. Fadel T R, Sharp F A, Vudattu N, Ragheb R, Garyu J, Kim D, Hong E, Li N, Haller G L, Pfefferle L D, Justesen S, Herold K C, Fahmy T M. A carbon nanotube-polymer composite for T-cell therapy. Nature nanotechnology. 2014; 9 : 639-47

32. Ragheb R R, Kim D, Bandyopadhyay A, Chahboune H, Bulutoglu B, Ezaldein H, Criscione J M, Fahmy T M. Induced clustered nanoconfinement of superparamagnetic iron oxide in biodegradable nanoparticles enhances transverse relaxivity for targeted theranostics. Magnetic resonance in medicine. 2013; 70 : 1748-60

33. Dasari M, Acharya A P, Kim D, Lee S, Lee S, Rhea J, Molinaro R, Murthy N. H-gemcitabine: a new gemcitabine prodrug for treating cancer. Bioconjugate chemistry. 2013; 24 : 4-8

34. Park W, Kim D, Kang H C, Bae Y H, Na K. Multi-arm histidine copolymer for controlled release of insulin from poly(lactide-co-glycolide) microsphere. Biomaterials. 2012; 33 : 8848-57

35. Ning X, Lee S, Wang Z, Kim D, Stubblefield B, Gilbert E, Murthy N. Maltodextrin-based imaging probes detect bacteria in vivo with high sensitivity and specificity. Nature materials. 2011; 10 : 602-7

Grants

1. Extracellular Vesicle-Based Intraocular Therapy Combined with Active Targeting of Ocular Neovascularization. NEI. Start Date: 2024. End Date: 2029.

2. MiPEP133, a New Tumor Suppressor for Ovarian Cancer. American Cancer Society. Start Date: 2024. End Date: 2027.

3. Extracellular Vesicle Therapy for Diabetic Retinopathy. NEI. Start Date: 2023. End Date: 2024.

4. Lymphatics and lymphangiogenesis in kidney function and inflammation. NIH. Start Date: 2019. End Date: 2024.

5. Extracellular Vesicle Therapy for Diabetic Retinopathy. NEI. Start Date: 2023. End Date: 2024.

Awards and Honors

no results

Education

1. Degree: Ph D. University of Utah. Date: 2009.


2. Degree: MS. University of Florida. Date: 2002.


3. Degree: BS. Ajou University. Date: 1999.

Administrative Assignments

no results